162 related articles for article (PubMed ID: 37758411)
1. Measuring Symptom Severity and Quality of Life in Mastocytosis.
Pyatilova P; Siebenhaar F
Immunol Allergy Clin North Am; 2023 Nov; 43(4):751-762. PubMed ID: 37758411
[TBL] [Abstract][Full Text] [Related]
2. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium.
Pyatilova P; Akin C; Alvarez-Twose I; Arock M; Bonadonna P; Brockow K; Butterfield JH; Broesby-Olsen S; Carter MC; Castells M; George TI; Gotlib J; Greiner G; Gülen T; Hartmann K; Hermine O; Horny HP; Jawhar M; Lange M; Lyons JJ; Maurer M; Metcalfe DD; Nedoszytko B; Niedoszytko M; Orfao A; Reiter A; Schwaab J; Sotlar K; Sperr WR; Triggiani M; Valent P; Siebenhaar F
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2015-2024. PubMed ID: 35724950
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis.
van Anrooij B; Kluin-Nelemans JC; Safy M; Flokstra-de Blok BM; Oude Elberink JN
Allergy; 2016 Nov; 71(11):1585-1593. PubMed ID: 27089859
[TBL] [Abstract][Full Text] [Related]
5. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Taylor F; Akin C; Lamoureux RE; Padilla B; Green T; Boral AL; Mazar I; Mar B; Shields AL; Siebenhaar F
Orphanet J Rare Dis; 2021 Oct; 16(1):414. PubMed ID: 34627355
[TBL] [Abstract][Full Text] [Related]
6. Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Taylor F; Li X; Yip C; Padilla B; Mar B; Green T; Oren R; Boral AL; Lin HM; Shields AL; Gotlib J
Leuk Res; 2021 Sep; 108():106606. PubMed ID: 34004551
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
Nanagas VC; Kovalszki A
Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
[TBL] [Abstract][Full Text] [Related]
8. Clinical challenge for gastroenterologists-Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review.
Elvevi A; Elli EM; Lucà M; Scaravaglio M; Pagni F; Ceola S; Ratti L; Invernizzi P; Massironi S
World J Gastroenterol; 2022 Aug; 28(29):3767-3779. PubMed ID: 36157547
[TBL] [Abstract][Full Text] [Related]
9. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.
Lübke J; Schwaab J; Christen D; Elberink HO; Span B; Niedoszytko M; Gorska A; Lange M; Gleixner KV; Hadzijusufovic E; Solomianyi O; Angelova-Fischer I; Zanotti R; Bonifacio M; Bonadonna P; Shoumariyeh K; von Bubnoff N; Müller S; Perkins C; Elena C; Malcovati L; Hagglund H; Mattsson M; Parente R; Varkonyi J; Fortina AB; Caroppo F; Zink A; Brockow K; Breynaert C; Bullens D; Yavuz AS; Doubek M; Sabato V; Schug T; Niederwieser D; Hartmann K; Triggiani M; Gotlib J; Hermine O; Arock M; Kluin-Nelemans HC; Panse J; Sperr WR; Valent P; Reiter A; Jawhar M
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):581-590.e5. PubMed ID: 36403897
[TBL] [Abstract][Full Text] [Related]
11. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
Azaña JM; Torrelo A; Matito A
Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106
[TBL] [Abstract][Full Text] [Related]
12. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Bossi G; Brazzelli V; De Amici M; Pietra D; Raviola C; Naso M; Regalbuto C; Boselli F; Fortina V; Marseglia GL
Ital J Pediatr; 2023 Jan; 49(1):6. PubMed ID: 36639823
[TBL] [Abstract][Full Text] [Related]
15. [Mastocytosis in children].
Wassmer H; Hartmann K
Dermatologie (Heidelb); 2023 May; 74(5):323-329. PubMed ID: 37140636
[TBL] [Abstract][Full Text] [Related]
16. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
Pardanani A
Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.
Siebenhaar F; von Tschirnhaus E; Hartmann K; Rabenhorst A; Staubach P; Peveling-Oberhag A; Wagner N; Martus P; Carter MC; Metcalfe DD; Church MK; Maurer M; Weller K
Allergy; 2016 Jun; 71(6):869-77. PubMed ID: 26797792
[TBL] [Abstract][Full Text] [Related]
20. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis.
Riffel P; Schwaab J; Lutz C; Naumann N; Metzgeroth G; Fabarius A; Schoenberg SO; Hofmann WK; Valent P; Reiter A; Jawhar M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):945-951. PubMed ID: 31980928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
